Our post-graduate year 2 (PGY2) oncology pharmacy residency program helps residents develop expertise and competency in providing pharmaceutical care services to cancer patients in both inpatient and ambulatory settings. Required rotations include adult and pediatric oncology, bone marrow transplant, oncology specialty pharmacy, infusion and hospice/palliative care. Longitudinal experiences include administration, research, tumor board attendance, participation in an oncology pharmacy and therapeutics (P&T) committee. Residents will also have opportunities to teach through direct precepting of PGY1 residents and students as well as opportunities to lecture in the oncology module and participate in the oncology elective at Idaho State University.
This 12 month program offers an approximately $61,000 stipend, benefits, and paid time off.
Residency Start Date: First or second Monday in July (depending on when the holiday falls)
Core Rotations
- Orientation - 2 weeks
- Medical oncology/infusion - 6 weeks
- Oncology specialty pharmacy - 6 weeks
- Inpatient oncology - 5 weeks
- Blood and marrow transplant - 5 weeks
- Pediatric oncology - 5 weeks
- Hospice/palliative care - 4 weeks
- Precepting - 4 weeks
Modified Rotations
- Radiation oncology (Nampa) - 3 weeks
- Rural oncology (Fruitland) - 1 week
- Elective option - 4 weeks
Longitudinal Rotations
Projects
Resident will complete numerous projects throughout the residency year and select one major project to present at the Mountain States Residency Conference. This will include an abstract and 15 minute power point presentation. After returning from Mountain States, the project will be written in manuscript form prior to residency completion. Residents are encouraged to publish this manuscript or work with the RPD to find other opportunities to publish and/or present. The resident will select one preceptor to serve as a preceptor for the major residency project. The resident and the preceptor will meet on a regular basis to discuss details of the project, timelines, obstacles and accomplishments. Major project timeline:
- Project ideas & discussion – Nov 1
- Project selection – Dec 1
- Timeline – Dec 1
- Goals and objectives – Dec 15
- Abstract (rough draft) for Mountain States Residency Conference – Jan 15
- PowerPoint presentation (rough draft) – April 15
Precepting Opportunities
- Opportunity to serve as the primary preceptor for one PGY1 resident and be involved with precepting P4 APPE students
- Assist in updating the current rotation materials
- Schedule rotation activities
- Oversee all projects done by the student/resident and ensure deadlines are met
- Contribute to the evaluation of the student/resident
Staffing Requirements
- Residents will be required to staff one day every other week (on average) or a total of 2 shifts per 4 week schedule
- SLCI is outpatient based and currently closed on weekends, so this will occur during the week
- Certain rotations may require weekend activities, but this will be discussed with primary preceptors before scheduling
Application Requirements and Process
Application Deadline: first Friday in January
Requirements: Applicants must have a PharmD degree or equivalent and eligibility for Idaho Licensure, which must be obtained prior to the start of the residency.
- Submit an application via PhORCAS by the last Friday in January; application to include:
- Letter of Intent
- Three letters of recommendation (one must be from the PGY1 RPD)
- Current CV
- Pharmacy Transcripts
- Applicants must also complete a St. Luke's online application by the same deadline
- Interviews will be conducted in late January through the first week of March
Contact Information
For questions, please contact:
Robert Mancini, PharmD, BCOP, FHOPA
BMT Pharmacy Program Coordinator and PGY2 Oncology Residency Program Director
(208) 381-4141
Email: [email protected]
Leslie LaMontagne, PharmD, BCOP
PGY2 Residency Program Coordinator
Email: [email protected]
Accreditation
The PGY2 Oncology Pharmacy Residency conducted by St. Luke's Health System, Boise, ID is accredited by ASHP.